Jun Gong
@jgong15
Followers
2K
Following
7K
Media
664
Statuses
3K
Medical oncologist and researcher in gastrointestinal and genitourinary cancers @CedarsSinai. Hematology/Oncology fellowship @cityofhope
Los Angeles, CA
Joined November 2016
Today is #WorldCancerDay thank you @KTLA for this interview & raising cancer awareness @LuParker @glenwalkerktla . @CSCancerCenter @OncoAlert @Larvol @OPENoncology @oncodaily @CParkMD @medicalwatchBC @MOASC_Office @OncoReporte @LinksCancer @OncBrothers .
ktla.com
Los Angeles news and live streaming video
1
17
38
RT @AbdulhaqHaifaa: Thank you @binaytara for holding the conference Updates in Hematology and Oncology @UCSFFresno and thank you to our out….
0
3
0
RT @DDominguezMD: Congrats to Dr Labadie, future Dr Fan and the rest of the @cityofhope team for getting this out. Preserved survival wit….
0
2
0
RT @MarkYarchoan: Disappointing news in #HCC: the much-anticipated Phase 3 IMbrave152 trial (atezo/bev ± tiragolumab) has quietly read out….
0
10
0
RT @FASinicropeMD: Implications of BRAF V600E in dMMR/MSI-H pts treated with ICIs. Prognostic impact of the BRAF V600E mutation in patie….
0
13
0
RT @neerajaiims: Just came online in @TheLancet 👉Our two papers on improved OS with Enzalutamide + Talazoparib in mCRPC #ProstateCancer in….
0
58
0
RT @tuttsakhil: Adjuvant Chemoradiation and Immunotherapy for Extrahepatic Cholangiocarcinoma and Gallbladder Cancer .👉ACCORD: camrelizumab….
jamanetwork.com
This randomized clinical trial evaluates the safety and efficacy of immunotherapy combining with chemoradiotherapy.
0
3
0
RT @neerajaiims: Breaking News from ph3 Embark trial👉Enzalutamide+ADT improve overall survival (OS) vs. ADT alone in Non-Metastatic HSPC #P….
0
63
0
RT @weldeiry: FDA Approves SIR-Spheres for Liver Cancer Treatment.
curetoday.com
The FDA approved SIR-Spheres Y-90 resin microspheres for unresectable liver cancer, the only radioembolization approved in the U.S. for both HCC and mCRC.
0
2
0
RT @OncData: Watch as @SFreedlandMD and @jgong15 of @CedarsSinai explore the phase 3 #CHALLENGE trial, presented at #ASCO25, which showed e….
0
1
0
Always great catching up with @SFreedlandMD expert in #diet/exercise in cancer care to discussed #CHALLENGE trial of structured exercise in #colorectalcancer & potential implications on other cancers. Thanks @OncData for hosting!. @OncoAlert
Watch as @SFreedlandMD and @jgong15 of @CedarsSinai explore the phase 3 #CHALLENGE trial, presented at #ASCO25, which showed encouraging results for the impact of a structured #exercise program on disease-free survival in #colon #cancer. Watch here!
1
7
15
RT @LancetGastroHep: New @TheLancetOncol - Patterns in genomic mutations among patients with early-onset colorectal cancer: an internationa….
thelancet.com
Within hypermutated colorectal cancer, younger patients exhibited a higher mutational burden than older patients. Our study reveals an abnormal accumulation of distinct somatic mutations in hypermu...
0
8
0
RT @RonDePinho: Important @Nature study reports signatures caused by the bacteria-produced mutagen colibactin had higher mutation loads in….
0
4
0
RT @MarioBalsaMD: Almost forgot a favorite one! 💥 The phase III TALENTACE trial in intermediate/high burden HCC shows:. 🎯ORR 49% vs 34%.🎯mP….
0
18
0
RT @whosainastro: 1/.Why is Ki-67 called Ki-67? And why am I attaching a photo of this beautiful city to the tweet? .If you work in patholo….
0
149
0
RT @Erman_Akkus: 📢Proffered paper #ESMOGI25 @myESMO. ➡️ALTAIR study.➡️resected CRC, ctDNA follow-up, if positive ➡️preemptive FTD/TPI vs pl….
0
6
0
RT @DrYukselUrun: In the 27,010-person PREEMPT CRC study:.🩸🧬79.2% sensitivity for CRC.🩸🧬 91.5% specificity for advanced neoplasia.BUT:detec….
0
9
0
Join us for this joint @AmericanCancer @LACareHealth free #CME webinar on #prostatecancer screening . Thursday, July 17, 2025.12-1:30 pm PST. Register at: . @OncoAlert @healthaccess @ACSCAN @ACSNews @ACSCANCA
0
7
10